ATTCK20: Phase I started

Unum began an open-label, dose-escalation, Chinese Phase I trial to evaluate ATTCK20 therapy plus IL-2 in about 18 patients ages 6 months to 80 years with CD20-positive Beta cell malignancies, such as...